Summary

Administration of everolimus (combined with exemestane in real-world conditions extends progression-free survival in postmenopausal women with hormone receptor-positive advanced breast cancer. Data from the German Breast Cancer Treatment With Afinitor (Everolimus) and Exemestane for ER+ Women trial [BRAWO] are discussed in this article.